Abstract Number: 173 • 2013 ACR/ARHP Annual Meeting
HLA-DRB1*08:02 Is Associated With Bucillamine-Induced Proteinuria In Japanese Rheumatoid Arthritis Patients: A Case-Control Study
Background/Purpose: Bucillamine (Buc) is one of the commonly used disease-modifying anti-rheumatic drugs (DMARDs) in Japan. Drug-induced proteinuria can occur in rheumatoid arthritis (RA) patients treated…Abstract Number: 442 • 2013 ACR/ARHP Annual Meeting
Tolerability and Non-Serious Adverse Events In Rheumatoid Arthritis Patients Treated With Tofacitinib As Monotherapy Or In Combination Therapy
Background/Purpose: Tofacitinib is a novel, oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Tolerability remains an ill-defined construct in clinical trials.…Abstract Number: 2626 • 2013 ACR/ARHP Annual Meeting
Infliximab For Sight-Threatening and Refractory Uveitis Of Behcet’s Syndrome
Background/Purpose: Uncontrolled studies suggest a beneficial effect of infliximab in the treatment of severe uveitis of BS. The majority of these studies had short observation…Abstract Number: 459 • 2013 ACR/ARHP Annual Meeting
Transaminase Levels and Hepatic Events Observed During Tocilizumab Treatment: Pooled Analysis Of Long-Term Clinical Trial Safety Data In Patients With Rheumatoid Arthritis
Background/Purpose: The interleukin-6 receptor inhibitor tocilizumab (TCZ) has demonstrated efficacy in improving signs/symptoms, reducing joint damage, and improving function and is well tolerated in patients…Abstract Number: 2628 • 2013 ACR/ARHP Annual Meeting
Immunogenicity Of Infliximab Modulates Efficacy and Safety In Behcet’s Disease Patients With Uveitis
Background/Purpose: Infliximab (IFX) suppresses ocular attacks in Behcet’s disease (BD) with uveitis, resulting in favorable long-term visual prognosis. However, some patients had ocular attacks which…Abstract Number: 2351 • 2013 ACR/ARHP Annual Meeting
Tocilizumab In Patients With Rheumatoid Arthritis and Rates Of Malignancy: Results From Long-Term Extension Clinical Trials
Background/Purpose: Malignancy is a potential risk of immunomodulatory treatments and may be increased in patients (pts) with rheumatoid arthritis (RA). The risk of malignancy was…Abstract Number: 2362 • 2013 ACR/ARHP Annual Meeting
Incidence Of Adverse Events In Patients With Rheumatoid Arthritis and Spondyloarthritis Exposed To Anti-TNF Therapy. Data From The Brazilian Registry For Monitoring Of Biologic Therapies In Rheumatic Diseases (BiobadaBrasil)
Background/Purpose: The safety profile of a-TNF biologic drugs might have substantial regional differences due to geographic and socio economic factors and to epidemiology of infectious…Abstract Number: 2048 • 2013 ACR/ARHP Annual Meeting
Risk Factors For Glucocorticoids-Induced Diabetes In Patients With Rheumatic Diseases
Background/Purpose: Since the efficacy of glucocorticoids for various rheumatic diseases was reported, glucocorticoids are still one of the important therapeutic agents in the current treatment…Abstract Number: 1865 • 2013 ACR/ARHP Annual Meeting
Complement Activation and Anaphylatoxin Generation In Response To Staphylococcal Protein A Exposure: Ex Vivo and In Vivo Human Studies
Background/Purpose: PRTX-100, a highly-purified GMP staphylococcal protein A (SpA), is currently in clinical trials treating patients with active rheumatoid arthritis (RA). It has been reported…Abstract Number: 2158 • 2012 ACR/ARHP Annual Meeting
Baseline Folate Related Biomarkers in Serum and erythrocytes Are Not Associated with Methotrexate Response and Adverse Events in Rheumatoid Arthritis
Background/Purpose: Methotrexate (MTX) is the most commonly used drug in rheumatoid arthritis (RA). 30% of patients fail to respond to the drug or suffer from…Abstract Number: 2161 • 2012 ACR/ARHP Annual Meeting
Methotrexate Polyglutamate Concentrations in Erythrocytes Are a Potential Tool for Therapeutic Drug Monitoring of Methotrexate Response in Rheumatoid Arthritis
Background/Purpose: Methotrexate (MTX) is the most commonly used drug in rheumatoid arthritis (RA). 30% of patients fail to respond to the drug or suffer from…Abstract Number: 1853 • 2012 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patients’ Experiences of Medication Side Effects and Subsequent Decision Making about Medications
Background/Purpose: Medication adherence in rheumatoid arthritis (RA) patients can be influenced by their previous experiences with medication side effects. Negative experiences may lead patients to…Abstract Number: 1854 • 2012 ACR/ARHP Annual Meeting
The Safety of Anti-TNF Biologic Agents in Rheumatoid Arthritis – A Meta-Analysis of 35 RCTs
Background/Purpose: The objectives of this systematic review were to study and update the safety of anti-TNF agents. We examined whether etanercept (ETN), compared to the…Abstract Number: 1298 • 2012 ACR/ARHP Annual Meeting
Improvement of Treatment Outcome of Rheumatoid Arthritis with Salazosulfapyridine by Pharmacogenetic Approach
Background/Purpose: Salazosulfapyridine (SASP) is acetylated in liver by N-acetyltransferase2 (NAT2) in the track of metabolism. Previous studies have shown that genotyping of NAT2 is adequate…Abstract Number: 1242 • 2012 ACR/ARHP Annual Meeting
Use of Anti-Tumor Necrosis Factor Therapy Is Associated with Reduced Cardiovascular Event Risk in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased risks for cardiovascular (CV) comorbidities because of an increased prevalence of traditional CV risk factors and the…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- Next Page »